.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after an average consequence of 11 months, patients along with metastatic stomach cysts that acquired biomarker-matched therapies based on distributing tumor DNA profiling presented a greater clinical benefit than those getting incomparable therapy.